# Eli Lilly and Company

Type: Company (LLY)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/eli-lilly-and-company
Canonical HTML page: https://gethealthbrief.com/entity/eli-lilly-and-company

## Timeline

- **2026-06**: Off-Label Drug Mandate — The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process.
- **2026-05**: Vida Health Assessment — Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse.
- **2026-02**: Employer Imposes Vida Health Requirement — Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits.
- **2025-12**: Zepbound Prescription Issued — David Davis receives a prescription for Zepbound from his primary care doctor to treat obstructive sleep apnea.

## Recent coverage (4 stories)

### Wegovy 7.2 mg Shows 19% Weight Loss; Novo Sues Lilly Over Patient Misinformation
2026-07-21 14:14:59 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

The suit ensures obesity patients receive the latest efficacy data, as Novo contends Lilly’s ads deny consumers a full picture of treatment options, potentially swaying prescriptions.
Full story: https://gethealthbrief.com/story/novo-lilly-glp1-lawsuit-patient-data

### Eli Lilly’s Rs 2.15 lakh cancer pill enters India: Will precision oncology widen the equity gap?
2026-06-26 01:54:12 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Full story: https://gethealthbrief.com/story/tanstrive-india-launch-access-cost

### Telehealth Gatekeepers Block 57-Year-Old’s GLP-1 Prescription, Sparking Doctor Alarm
2026-06-14 21:07:57 · Sentiment: Bearish · Impact: 6/10 · Sources: 7

A California man’s employer-mandated use of Vida Health stalled his Zepbound treatment for obstructive sleep apnea, highlighting how telehealth platforms are overriding primary care physicians to reduce obesity drug costs.
Full story: https://gethealthbrief.com/story/telehealth-glp-1-gatekeeping

### Fisher Asset Management Boosts Eli Lilly Stake Amid GLP-1 Expansion
2026-03-03 00:58:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Full story: https://gethealthbrief.com/story/fisher-asset-management-eli-lilly-stake-increase

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.